Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alkermes PLC

www.alkermes.com

Latest From Alkermes PLC

Keeping Track: CDER Approves Its First Two Novel Agents Of 2019

The latest drug development news and highlights from our US FDA Performance Tracker.
US FDA Performance Tracker Drug Review

Keeping Track: FDA Approves First Generic Advair, But Alkermes And Sunovion Land CRLs

The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation

Hazards Ahead For New Drugs At US FDA Amid Safety Concerns, Shutdown Disruption

The pipeline for new drug candidates remains healthy as 2019 begins, with almost 40 novel agents already under FDA review. But the chances of another record-breaking year are threatened by a confluence of safety issues that are putting risk management back in the spotlight – and by the widening ripple effects of the recent US government shutdown.

Drug Review Approvals

Editas Seeks New CEO, CFO Ahead of CRISPR Specialist's New Clinical Era

Katrine Bosley’s announced departure as Editas' CEO follows news its CFO Andrew Hack is leaving to join Bain Capital - and just as the gene-editing specialist prepares to administer its ground-breaking CRISPR medicine to humans in the clinic.

Leadership Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
      • Pulmonary
  • Therapeutic Areas
  • Cancer
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Alkermes Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Ireland
  • Parent & Subsidiaries
  • Alkermes PLC
  • Senior Management
  • Richard F Pops, Chmn. & CEO
    James M Frates, SVP, CFO
    Blair C Jackson, SVP, Bus. Dev.
    Mark Stejbach, SVP, Chief Commercial Officer
    James Robinson, Pres. & COO
  • Contact Info
  • Alkermes PLC
    Phone: 1 772 8000
    1 Burlington Rd.
    Connaught House
    Dublin 4, MA
    Ireland
Advertisement
Advertisement
UsernamePublicRestriction

Register